Roles for Innate Immunity in Combination Immunotherapies
Name
nihms911205.pdf
Size
481.32 KB
Format
Adobe PDF
Checksum (MD5)
a484623acdd76c99d3e5525bbeabf3a2
Author(s)
Moynihan, Kelly Dare
Irvine, Darrell J
Date Issued
October 2017
Journal
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Citation
Moynihan, Kelly D., and Darrell J. Irvine. “Roles for Innate Immunity in Combination Immunotherapies.” Cancer Research, vol. 77, no. 19, Oct. 2017, pp. 5215–21.
Version
Author's final manuscript
Abstract
Immunity to infectious agents involves a coordinated response of innate and adaptive immune cells working in concert, with many feed-forward and regulatory interactions between both arms of the immune system. In contrast, many therapeutic strategies to augment immunity against tumors have focused predominantly on stimulation of adaptive immunity. However, a growing appreciation of the potential contributions of innate immune effectors to antitumor immunity, especially in the context of combination immunotherapy, is leading to novel strategies to elicit a more integrated immune response against cancer. Here we review antitumor activities of innate immune cells, mechanisms of their synergy with adaptive immune responses against tumors, and discuss recent studies highlighting the potential of combination therapies recruiting both innate and adaptive immune effectors to eradicate established tumors.
MIT Department
Massachusetts Institute of Technology. Center for Materials Science and Engineering
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Ragon Institute of MGH, MIT and Harvard
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1158/0008-5472.CAN-17-1340
